Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast.

Published on Mar 1, 2020in Annals of Oncology18.274
· DOI :10.1016/J.ANNONC.2019.11.022
S. Di Cosimo15
Estimated H-index: 15
Valentina Appierto15
Estimated H-index: 15
+ 9 AuthorsMaria Grazia Daidone59
Estimated H-index: 59
#1Isaac Garcia-Murillas (ICR: Institute of Cancer Research)H-Index: 21
#2Neha Chopra (ICR: Institute of Cancer Research)H-Index: 5
Last. Nicholas C. Turner (ICR: Institute of Cancer Research)H-Index: 55
view all 22 authors...
Importance Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients are at risk of relapse. Objective To assess the clinical validity of molecular relapse detection with circulating tumor DNA (ctDNA) analysis in early-stage breast cancer. Design, Setting, and Participants This prospective, multicenter, sample collection, validation study conducted at 5 United Kingdom medical centers from November 24, 2011, to Oct...
55 CitationsSource
#1Giulia Siravegna (UNITO: University of Turin)H-Index: 32
#2Benedetta MussolinH-Index: 17
Last. Alberto Bardelli (UNITO: University of Turin)H-Index: 86
view all 11 authors...
Abstract Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a variety of clinical applications. ctDNA is being used to genotype solid cancers non-invasively, to track tumor dynamics and to detect the emergence of drug resistance. In a few settings, liquid biopsies have already entered clinical practice. For example, ctDNA is used to guide treatment in a subset of lung cancers. ...
52 CitationsSource
Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological si...
200 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 58
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 24
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 118
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
9,002 CitationsSource
#1Monica Morrow (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 82
#2Steven J. KatzH-Index: 61
16 CitationsSource
Cited By1